Arcellx (ACLX) Common Equity (2021 - 2025)
Arcellx (ACLX) recorded quarterly Common Equity of $402.4 million in Q4 2025, down 8.72% quarter-over-quarter from $440.8 million in Q3 2025, and down 11.53% on a YoY basis from $454.8 million in Q4 2024.
Arcellx (ACLX) Common Equity (2021 - 2025) Analysis & Trends
Arcellx's Common Equity history runs 5 years deep, the most recent figure standing at $402.4 million for Q4 2025.
- In Q4 2025, Common Equity fell 11.53% year-over-year to $402.4 million; the TTM figure through Dec 2025 stood at $402.4 million (down 11.53% YoY), while the FY2025 annual figure was $402.4 million, down 11.53% from the prior year.
- Common Equity was $402.4 million for Q4 2025 at Arcellx, down from $440.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $496.6 million in Q1 2024 to a low of -$205.0 million in Q4 2022.
- Historically, Common Equity has averaged $255.9 million across 5 years, with a median of $313.7 million in 2022.
- Biggest YoY gain for Common Equity was 464.65% in 2022; the steepest drop was 68.67% in 2022.
- A 5-year view of Common Equity shows it stood at -$121.5 million in 2021, then sank by 68.67% to -$205.0 million in 2022, then soared by 336.82% to $485.4 million in 2023, then declined by 6.3% to $454.8 million in 2024, then dropped by 11.53% to $402.4 million in 2025.
- The last three Common Equity figures came in at $402.4 million (Q4 2025), $440.8 million (Q3 2025), and $392.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 402.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 402.35 Mn |
| Sep 30, 2025 | 440.78 Mn |
| Jun 30, 2025 | 392.22 Mn |
| Mar 31, 2025 | 416.91 Mn |
| Dec 31, 2024 | 454.79 Mn |
| Sep 30, 2024 | 483.02 Mn |
| Jun 30, 2024 | 487.16 Mn |
| Mar 31, 2024 | 496.57 Mn |
| Dec 31, 2023 | 485.38 Mn |
| Sep 30, 2023 | 266.13 Mn |
| Jun 30, 2023 | 293.67 Mn |
| Mar 31, 2023 | 303.72 Mn |
| Dec 31, 2022 | -204.95 Mn |
| Sep 30, 2022 | 236.28 Mn |
| Jun 30, 2022 | 323.62 Mn |
| Mar 31, 2022 | 227.94 Mn |
| Dec 31, 2021 | -121.52 Mn |
| Sep 30, 2021 | -103.80 Mn |
| Jun 30, 2021 | -88.75 Mn |
| Mar 31, 2021 | -74.23 Mn |